Molecular Imaging of the Lung - Phase 2 (R01)
The summary for the Molecular Imaging of the Lung - Phase 2 (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Molecular Imaging of the Lung - Phase 2 (R01): This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications to develop novel in vivo imaging technologies using molecular probes that target pathways or cells involved in the pathobiology of pulmonary diseases. The long-term goal of this program is to develop novel molecular imaging entities and approaches that facilitate early detection and diagnosis of lung disease, enable noninvasive monitoring of lung disease progression and prognosis, and accelerate progress of cell-specific drug delivery and therapies.The previous FOA (RFA-HL-12-036 - Phase 1) supported projects to develop and validate innovative novel imaging agents and approaches that included target selection, probe development and production, and initial characterization of the probe. Phase 2 of this initiative will support studies that advance translation of identified probes and associated imaging approaches from animal models into applicability for human lung diseases. Phase 2 studies must include work performed in vivo using appropriate animal models of lung diseaseand studies using human tissues and/or cells. Applications proposing Investigational New Drug (IND)-enabling studies of novel probes and imaging approaches are encouraged. Applicants are not required to have been funded in Phase 1 (RFA-HL-12-036) in order to submit applications for Phase 2.
|Federal Grant Title:||Molecular Imaging of the Lung - Phase 2 (R01)|
|Federal Agency Name:||National Institutes of Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-HL-16-001|
|Type of Funding:||Grant|
|CFDA Descriptions:||Lung Diseases Research|
|Current Application Deadline:||Jun 15, 2015|
|Original Application Deadline:||Jun 15, 2015|
|Posted Date:||Mar 17, 2015|
|Creation Date:||Mar 17, 2015|
|Archive Date:||Jul 16, 2015|
|Total Program Funding:||$3,500,000|
|Maximum Federal Grant Award:||$450,000|
|Minimum Federal Grant Award:||none|
|Expected Number of Awards:||5|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
City or township governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Independent school districts
Private institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Special district governments
For profit organizations other than small businesses
Native American tribal governments (Federally recognized)
Native American tribal organizations (other than Federally recognized tribal governments)
Public housing authorities/Indian housing authorities
- Additional Information on Eligibility
- Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- Grant Announcement Contact
- NIH OER Webmaster
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
National Institutes of Health 301-496-3405
- Similar Government Grants
- • Advancing Novel Research Models to Study Idiopathic Pulmonary Fibrosis (U01 Clinical Trial...
- • Management of Asthma in Primary Care - Bioinformatics Center (U24 - Clinical Trial Require...
- • Management of Asthma in Primary Care - Clinical Center (UG3/UH3 - Clinical Trial Required)
- • Molecular Atlas of Lung Development Program (LungMAP) Phase 2 - Data Coordinating Center (...
- • Molecular Atlas of Lung Development Program (LungMAP) Phase 2 - Human Tissue Core (U01- Cl...
- • Pathogenesis of Sars Lung Disease: in Vitro Studies and Animal Models
- • Lung Response to Inhaled Highly Toxic Chemicals
- • Protein Interactions Governing Membrane Transport in Pulmonary Health and Disease (R01)
- More Grants from the National Institutes of Health
- • Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
- • A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
- • Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
- • HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
- • National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan...